Immunovant Inc. (IMVT)
IMVT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | IMVT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001764013 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $722.3M cash; operating cash flow -$98.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 206,947,758 (2026-11-03); 175,276,526 a year earlier; 144,661,930 three years earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2025-12-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Iselin, New Jersey, United States | PCAOB Form AP 2026-06-04 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $350.0M, sold $16.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2027 2026-09-30 | Not filed | -$97.2M | -$83.2M | $722.3M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2027 2026-06-30 | Not filed | -$153.2M | -$124.4M | $797.8M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2026 2026-03-31 | Not filed | -$147.9M | -$95.1M | $902.1M | No debt tags | Needs four quarters | 10-K 2026-05-20 |
| Q3 2026 2025-12-31 | Not filed | -$110.6M | -$92.3M | $994.5M | No debt tags | Needs four quarters | 10-Q 2026-02-06 |
| Q2 2026 2025-09-30 | Not filed | -$126.5M | -$102.5M | $521.9M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2026 2025-06-30 | Not filed | -$120.6M | -$117.4M | $598.9M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2025 2025-03-31 | Not filed | -$106.4M | -$110.6M | $714.0M | No debt tags | Needs four quarters | 10-K 2026-05-20 |
| Q3 2025 2024-12-31 | Not filed | -$111.1M | -$100.4M | $374.7M | No debt tags | Needs four quarters | 10-Q 2026-02-06 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-11-09 |
| Latest annual report | 10-K | 2026-05-20 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-07-22 |
Source: SEC EDGAR submissions feed, 653 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +12.0% |
| 1 month | +19.1% |
| 3 months | -18.3% |
| Year to date | +34.5% |
| 1 year | +49.8% |
| From 52-week high | -24.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TWST | Twist Bioscience Corporation | $105.04 | -5.88% | $7.0B |
| KOD | Kodiak Sciences Inc | $100.73 | -9.41% | $6.6B |
| IBRX | ImmunityBio Inc. | $5.98 | -0.66% | $6.4B |
| CGON | CG Oncology Inc. | $84.78 | +13.95% | $7.6B |
| SRRK | Scholar Rock Holding Corporation | $44.54 | +3.09% | $5.4B |
| KRYS | Krystal Biotech Inc. | $297.90 | -2.40% | $8.8B |
| PCVX | Vaxcyte Inc. | $61.61 | -2.78% | $9.8B |
| QGEN | Qiagen N.V. Common Shares | $49.81 | -0.16% | $10.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier